Call us : +91-11-2874-2874   |   Email us :

Less  Polymeric Load

Less Polymeric Load

Polymer is one of the important components of any drug eluting stent. The anti restenotic efficacy of drug-eluting stent (DES) technology is based on the local delivery and modulated release of drug. Control of drug-release kinetics is a critical component of device efficacy and polymer helps in controlling release kinetics and acts as a glue to ensure drug concentration. Undoubtedly, polymer is an important component but we cannot ignore the ill-effects or long term effects associated with the polymer. The therapeutic effect of drug may conceal the initial inflammation associated with the polymer but what will happen when the drug will get released?

Drug gets released in 4-6 weeks but polymer stays forever. Prolonged Inflammatory Response, Delayed Re-endothelialization, Hypersensitivity & Aneurysms, Late Stent Thrombosis, Restenosis etc are the negative long-term effects  associated with the polymer.

Despite knowing the ill-effects of polymer, it has been used in the conventional Drug Eluting Stents. Infact, in the present scenario also companies are using durable polymers to coat the stent. But, is it right to ignore the problems associated with the polymer? Is is not easy to get away with polymers as they play vital role as a stent component. Can they be Ignored?

Now the question arises how to obviate a polymer???

To answer this question it is important to have something wherein release kintetics of the drug  can be controlled by an alternate mechanism without a polymer so that, controlled release of the drug can be maintained from 2-4weeks till the therapeutic effect of drug is there.

Biodegradable polymer is the solution and can serve the purpose by providing safety of BMS and efficacy of DES.

Biodegradable polymer is the solution to overcome the problems associated with the permanent polymer. Biodegradable polymer helps in controlled drug release. The polymer slowly degrades into smaller fragments, releasing a natural product, and there is controlled ability to release a drug. The drug slowly releases as polymer degrades. This means that after completion of its useful function, Biodegradable Polymer slowly degrades to inert organic monomers, thereby dissipating the risk associated with the long-term presence of durable polymer in the coronary vessel wall.

Once the drug and biodegradable polymer is eluted  the stent is closer to the long-term experience/risk profile of a BMS than a DES with a durable polymer